GB16361-2012

Specification for patient radiological protection and quality control in nuclear medicine

临床核医学的患者防护与质量控制规范

GB 16361-2012 est une norme nationale chinoise obligatoire en vigueur : Specification for patient radiological protection and quality control in nuclear medicine. Secteur : Alimentation. Thème principal : Sécurité des produits. Entrée en vigueur : 1 oct. 2012.

L’applicabilité dépend du périmètre du produit, de la voie de certification, des avis des autorités et des règles de transition. Demandez une traduction ou vérifiez la source avant d’utiliser cette fiche pour une décision de conformité.

Aperçu de conformité

Cet aperçu n’est actuellement disponible qu’en anglais.

Champ d’application

This standard applies to the use of radiopharmaceuticals in clinical nuclear medicine for both diagnosis and treatment within medical institutions. It explicitly excludes procedures involving particle source implantation. It is designed for healthcare facilities, nuclear medicine departments, and manufacturers of nuclear medicine equipment and radioactive drugs operating in the Chinese market.

Exigences techniques

The standard mandates strict justification for all nuclear medicine procedures, requiring that the expected clinical benefits outweigh potential radiation risks. It sets forth rigorous optimization of radiological protection requirements, dictating that the lowest possible amount of radiopharmaceutical activity should be administered to achieve the desired diagnostic image quality or therapeutic outcome. Special precautions are mandated for pregnant or breastfeeding women and children, including specific dose constraints and pregnancy avoidance periods. It establishes clear dose constraints for individuals exposed to patients, such as family members and the public. For instance, adult family members must not exceed 5 mSv, while infants and children are limited to 1 mSv. The standard also defines criteria for patient release, such as the requirement that patients treated with iodine-131 must not be discharged until their internal radioactivity falls below a specific threshold. Furthermore, the standard outlines comprehensive quality control protocols for both radiopharmaceuticals and nuclear medicine equipment. This includes strict purity controls (radionuclidic, radiochemical, and chemical), precise activity measurement using calibrated instrumentation, and regular performance testing of imaging devices like SPECT and PET systems. Medical institutions must establish a formal quality assurance program and maintain detailed procedural records.

Méthodes d’essai

The standard references various testing and estimation methods, including the evaluation of radiopharmaceutical purity and the calibration of activity meters using long-life reference sources like cesium-137. It provides methodologies for estimating patient absorbed doses using data from ICRP Publications 53, 80, and 106, and outlines dose rate measurements at fixed distances to evaluate exposure to personnel near treated patients. Equipment testing encompasses acceptance, status, and stability tests for gamma cameras, SPECT, and PET systems.

Questions fréquentes

What products and facilities are regulated under GB 16361-2012?

This standard applies to medical institutions using radiopharmaceuticals for clinical nuclear medicine diagnosis and therapy. It explicitly excludes particle source implantation procedures. It is relevant for manufacturers of nuclear medicine equipment and radiopharmaceuticals supplying the Chinese healthcare sector.

Are there any significant updates from the previous version of GB 16361?

The 2012 version transitions from relying on older domestic standards to aligning with newer international guidelines, such as IAEA Safety Report No.40 and No.63. It also integrates patient protection with quality control requirements and expands the appendices from 2 to 8, adding detailed dose estimation methods.

How does GB 16361-2012 differ from international standards like IAEA or ICRP?

The standard incorporates principles from IAEA Safety Reports and ICRP Publications regarding patient release and dose constraints. For example, it aligns with IAEA guidelines by specifying that patients treated with iodine-131 cannot be discharged until their internal activity drops below 400 MBq.

The summary above provides a high-level overview of GB 16361-2012. To ensure complete compliance for your medical devices and radiopharmaceutical products entering the Chinese market, a precise and professional translation of the full technical specifications is essential. Purchase our high-quality English translation of GB 16361-2012 today to access all detailed parameters, dose calculation tables, and testing procedures.

Indications d’applicabilité

Type: Santé et hygiène
CCS: C57
ICS: 13.280
Autorité compétente: National Health Commission
Comité technique: National Health Commission

Relations

Remplace:GB 16361-1996